(Q43152159)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Ina Weiner

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

1 reference

24 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

number of pages

10

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

209

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

175-184

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists

18 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-010-1785-Z

Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-010-1785-Z

Muscarinic agonists for the treatment of cognition in schizophrenia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-010-1785-Z

Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?

21 January 2018

1 reference

12 December 2020

Involvement of the dorsomedial striatum in behavioral flexibility: role of muscarinic cholinergic receptors

1 reference

12 December 2020

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic

1 reference

12 December 2020

D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats

1 reference

12 December 2020

Effects of cholinergic drugs on scopolamine-induced memory impairment in rhesus monkeys.

1 reference

12 December 2020

Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.

1 reference

12 December 2020

Towards a muscarinic hypothesis of schizophrenia.

1 reference

12 December 2020

Dopamine, prediction error and associative learning: a model-based account

1 reference

12 December 2020

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment

1 reference

12 December 2020

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

1 reference

12 December 2020

Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study

1 reference

12 December 2020

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex

1 reference

12 December 2020

Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome

1 reference

12 December 2020

To model a psychiatric disorder in animals: schizophrenia as a reality test

1 reference

12 December 2020

Pharmacology of memory: cholinergic-glutamatergic interactions.

1 reference

12 December 2020

Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia

1 reference

12 December 2020

Neural substrates of latent inhibition: the switching model

1 reference

12 December 2020

Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats

1 reference

12 December 2020

Glycine modulation of NMDA-evoked release of [3H]acetylcholine and [3H]dopamine from rat striatal slices.

1 reference

12 December 2020

Cholinergic effects on fear conditioning I: the degraded contingency effect is disrupted by atropine but reinstated by physostigmine

1 reference

12 December 2020

Context, time, and memory retrieval in the interference paradigms of Pavlovian learning

1 reference

12 December 2020

Nicotinic receptors and schizophrenia

1 reference

12 December 2020

High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation

1 reference

12 December 2020

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

D-cycloserine, a glycine site agonist, reverses working memory failure by hippocampal muscarinic receptor blockade in rats.

1 reference

12 December 2020

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

1 reference

12 December 2020

Construct Validity of the Animal Latent Inhibition Model of Selective Attention Deficits in Schizophrenia

1 reference

12 December 2020

N-methyl-D-aspartate-evoked release of acetylcholine from the medial septum/diagonal band of rat brain.

1 reference

12 December 2020

Scopolamine disrupts visual reversal without affecting the first discrimination

1 reference

12 December 2020

Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

1 reference

12 December 2020

The visual search analogue of latent inhibition: implications for theories of irrelevant stimulus processing in normal and schizophrenic groups

1 reference

12 December 2020

The evolution of drug development in schizophrenia: past issues and future opportunities

1 reference

12 December 2020

D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys.

1 reference

12 December 2020

Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.

1 reference

12 December 2020

Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs

1 reference

12 December 2020

Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function

1 reference

12 December 2020

Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

1 reference

12 December 2020

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

1 reference

12 December 2020

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

1 reference

12 December 2020

Cortical cholinergic transmission and cortical information processing in schizophrenia

1 reference

12 December 2020

N-methyl-D-aspartate-type receptors mediate striatal 3H-acetylcholine release evoked by excitatory amino acids

1 reference

12 December 2020

Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment

1 reference

12 December 2020

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis

1 reference

12 December 2020

The changing roles and targets for animal models of schizophrenia

1 reference

12 December 2020

Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?

1 reference

12 December 2020

Central cholinergic systems and cognition

1 reference

12 December 2020

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

1 reference

12 December 2020

Glycine-evoked release of [3H]acetylcholine from rat striatal slices is independent of the NMDA receptor

1 reference

12 December 2020

Cholinergic neurons of the adult rat striatum are immunoreactive for glutamatergic N-methyl-d-aspartate 2D but not N-methyl-d-aspartate 2C receptor subunits

1 reference

12 December 2020

Glycine(B) receptor antagonists and partial agonists prevent memory deficits in inhibitory avoidance learning.

1 reference

12 December 2020

Drug initiatives to improve cognitive function.

1 reference

12 December 2020

The pipeline and future of drug development in schizophrenia.

1 reference

12 December 2020

On the trail of a cognitive enhancer for the treatment of schizophrenia

1 reference

12 December 2020

Glycine stimulates the release of labeled acetylcholine but not dopamine nor glutamate from superfused rat striatal tissue.

1 reference

12 December 2020

Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics.

1 reference

12 December 2020

D-cycloserine, a modulator of the N-methyl-D-aspartate receptor, improves spatial learning in rats treated with muscarinic antagonist.

1 reference

12 December 2020

A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia

1 reference

12 December 2020

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

1 reference

12 December 2020

Muscarinic receptors as a target for drugs treating schizophrenia

1 reference

12 December 2020

Differential role of muscarinic transmission within the entorhinal cortex and basolateral amygdala in the processing of irrelevant stimuli

1 reference

12 December 2020

Glycine transport inhibitors and the treatment of schizophrenia

1 reference

12 December 2020

A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice

1 reference

12 December 2020

Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia

1 reference

12 December 2020

Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting

1 reference

12 December 2020

Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered

1 reference

12 December 2020

10.1007/S00213-010-1785-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20179909%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

18 January 2020

1006910138

0 references

1 reference